North China Pharmaceutical (SHA:600812) subsidiary Xiantai Pharmaceutical received good manufacturing practice compliance approval from the Hebei drug administrator for its production lines of ampicillin sodium, amoxicillin and amoxicillin heavy powder.
The inspection was conducted from Nov. 26 to Nov. 29, 2024, according to a Monday filing with the Shanghai bourse.
Ampicillin sodium is a broad-spectrum semi-synthetic penicillin. Amoxicillin is used to treat respiratory and urinary tract infections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.